UCLA's AD-NP1 Reverses Kidney Damage in Mice Within 7 Days by Blocking ENPP1
Updated
Updated · sflorg.com · Jun 16
UCLA's AD-NP1 Reverses Kidney Damage in Mice Within 7 Days by Blocking ENPP1
2 articles · Updated · sflorg.com · Jun 16
Summary
Seven days after treatment, UCLA’s AD-NP1 antibody improved kidney function in mice with induced renal injury and left their kidneys with less scarring.
The drug works by blocking ENPP1, a protein overproduced after injury that disrupts cellular energy use and suppresses the proliferation needed for tissue repair.
In separate knockout experiments, mice unable to produce ENPP1 showed sharply lower creatinine, BUN and cystatin C after 4 weeks than control mice, reinforcing the target’s role in recovery.
Kidney biopsies from people with chronic kidney disease also showed higher ENPP1 expression than healthy tissue, suggesting the mechanism may extend beyond mice.
AD-NP1 was already cleared for Phase 1 human trials in heart repair, and UCLA researchers now plan to seek kidney trials for acute injury and chronic disease.
Blocking a single protein regenerates kidneys in mice. What are the hidden risks of this powerful new approach?
A single drug repairs both heart and kidney damage. Is the era of universal organ regeneration upon us?
ENPP1 Inhibition by AD-NP1: Transforming Organ Regeneration and the Future of Kidney Disease Therapy
Overview
A major breakthrough in regenerative medicine was achieved when Arjun Deb’s team discovered AD-NP1, a molecule that rapidly reverses kidney damage in mice. This innovation targets the enzyme ENPP1, which is found at higher levels in diseased kidneys and disrupts the body’s natural healing. By inhibiting ENPP1, AD-NP1 restores the energy balance in cells and encourages healthy cells to multiply near injury sites, leading to effective repair and regeneration of kidney tissue. This discovery opens new possibilities for treating chronic kidney disease by harnessing the body’s own repair mechanisms.